)
Edge6 Mar 2026
Upvoted: The Story of Reddit
How Reddit built a unique platform around communities and conversation, turning human insight and intent into a distinctive business model.
Vor Biopharma
Vor Biopharma (VOR) investor relations material
Vor Biopharma Corporate presentation summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Corporate presentation summary6 Mar, 2026
Strategic ambition and platform
Aims to transform treatment of B cell-driven autoimmune diseases through selective BAFF/APRIL inhibition, targeting both upstream B cell survival and downstream antibody production.
Telitacicept is a dual BAFF/APRIL inhibitor with clinical validation in over eight autoimmune indications in China and a favorable safety profile in tens of thousands of patients.
Strong cash position of $450M, providing runway into mid-2028 and funding all key clinical milestones.
Myasthenia gravis (MG) program
MG represents a large and growing global opportunity, with ~260,000 diagnosed patients across key markets and a projected $10.8B market size by 2030.
Current therapies mainly target symptoms and IgG, leaving unmet needs for disease-modifying treatments that address IgA and IgM autoantibodies.
Telitacicept demonstrated the largest placebo-adjusted improvement in MG-ADL among leading mechanisms, with sustained and deepening benefit over 48 weeks.
Phase 3 trial in China met primary and secondary endpoints, showing significant improvements in MG-ADL and QMG scores, with durable efficacy and consistent reduction in IgG, IgA, IgM, and B cells.
Favorable safety profile observed, with no new safety signals and manageable adverse events.
Global Phase 3 trial underway, with topline data expected in 1H27.
Sjögren's disease (SD) program
SD is a large, underserved autoimmune disease with ~870,000 diagnosed patients across key markets and no approved disease-modifying systemic therapies.
Telitacicept showed statistically significant and clinically meaningful improvements in ESSDAI and ESSPRI scores, with robust, dose-dependent, and durable effects across systemic activity and symptoms.
Nearly 90% of patients reported improvement, and 3 in 4 achieved disease control as confirmed by physicians.
Consistent reduction in IgG, IgA, IgM, and B cells observed, supporting the mechanism of action.
Favorable safety profile consistent with other indications, with no new safety signals.
Global Phase 3 trial initiated in February 2026, with primary endpoint at 48 weeks.
Telitacicept IgA and IgM targeting advantage
Cash runway alignment with Phase 3 data readouts
Telitacicept performance on STAR responder index
Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.Research faster. Power your platform.
Next Vor Biopharma earnings date
Q4 202520 Mar, 2026
Vor Biopharma
Next Vor Biopharma earnings date
Q4 202520 Mar, 2026
The essential earnings season companion
The #1 app for qualitative research. Live earnings calls, AI chat, transcripts, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
I can't remember the last time an app had such a positive impact on my investment process.
)
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
I can't remember the last time an app had such a positive impact on my investment process.
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
)
)
Frequently asked questions
Vor Biopharma Inc. is a clinical-stage biotechnology company focused on developing innovative treatments for blood cancers. The company's approach combines cell and genome engineering to create therapies that target and treat hematological malignancies. Vor's proprietary platform primarily involves engineering hematopoietic stem cells (HSCs) to enhance their compatibility with targeted therapies. The lead product candidate, an engineered HSC known as tremtelectogene empogeditemcel (trem-cel), is currently in clinical trials for the treatment of acute myeloid leukemia (AML). Vor is also working on additional therapies that involve chimeric antigen receptor T-cells (CAR-T) and antibody-drug conjugates to further expand its cancer treatment portfolio. The company is headquartered in Cambridge, Massachusetts, and its shares are listed on the Nasdaq.
Quartr provides global coverage of all investor relation material from public companies.
Mobile app: Research anytime, anywhere with the #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.
Desktop (Quartr Pro): The leading platform for qualitative research, used daily by top firms and financial institutions.
Quartr API: Build custom solutions powered by live earnings calls, live transcripts, filings and reports, slide presentations, and more.
Yes, the Quartr mobile app is free on both iOS and Android.
Yes. Quartr provides global, industry-leading live coverage of company events such as regular earnings calls, capital markets days, M&A announcements, and investor conferences. Live with zero delays. Just click and listen.
Yes, capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Yes. Follow the companies that matter to you. Get a personalized feed with real-time updates, a tailored earnings calendar, and instant alerts when earnings calls go live.
Yes. Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned, regardless of who's talking.
Explore our global coverage